Pharsight

Viberzi is owned by Allergan Holdings.

Viberzi contains Eluxadoline.

Viberzi has a total of 20 drug patents out of which 0 drug patents have expired.

Viberzi was authorised for market use on 27 May, 2015.

Viberzi is available in tablet;oral dosage forms.

Viberzi can be used as treatment of pain associated with irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline); treatment of irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline)., treatment of irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline), treatment of irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline)., reduction of the frequency of abdominal pain and diarrhea, in an inflammatory bowel disease with diarrhea (ibs-d) patient, with eluxadoline twice daily with food, treatment of pain associated with irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline).

The generics of Viberzi are possible to be released after 14 March, 2033.

Application	Filing Date	Opposition Party	Legal Status
EP14774006A	2019-05-28	Sandoz AG	Opposition rejected

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10213415	ALLERGAN HOLDINGS	Compounds as opioid receptor modulators	Mar, 2025 (1 year, 9 months from now)
US7786158	ALLERGAN HOLDINGS	Compounds as opioid receptor modulators	Mar, 2025 (1 year, 9 months from now)
US8609709	ALLERGAN HOLDINGS	Compounds as opioid receptor modulators	Mar, 2025 (1 year, 9 months from now)
US9115091	ALLERGAN HOLDINGS	Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl—1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid	Jul, 2028 (5 years from now)
US8691860	ALLERGAN HOLDINGS	Crystals and process of making 5-({(2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(-4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid	Jul, 2028 (5 years from now)
US7741356	ALLERGAN HOLDINGS	Compounds as opioid receptor modulators	May, 2029 (5 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9205076	ALLERGAN HOLDINGS	Compounds as opioid receptor modulators	Mar, 2025 (1 year, 9 months from now)
US8344011	ALLERGAN HOLDINGS	Compounds as opioid receptor modulators	Mar, 2025 (1 year, 9 months from now)
US9700542	ALLERGAN HOLDINGS	Compounds as opioid receptor modulators	Mar, 2025 (1 year, 9 months from now)
US8772325	ALLERGAN HOLDINGS	Compounds as opioid receptor modulators	Mar, 2025 (1 year, 9 months from now)
US9364489	ALLERGAN HOLDINGS	Crystals and process of making 5-({[2-amino-3-(4-Carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid	Jul, 2028 (5 years from now)
US9789125	ALLERGAN HOLDINGS	Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid	Jul, 2028 (5 years from now)
US9675587	ALLERGAN HOLDINGS	Opioid receptor modulator dosage formulations	Mar, 2033 (9 years from now)
US11090291	ALLERGAN HOLDINGS	Opioid receptor modulator dosage formulations	Mar, 2033 (9 years from now)
US11229627	ALLERGAN HOLDINGS	Opioid receptor modulator dosage formulations	Mar, 2033 (9 years from now)
US11007179	ALLERGAN HOLDINGS	Opioid receptor modulator dosage formulations	Mar, 2033 (9 years from now)
US11160792	ALLERGAN HOLDINGS	Opioid receptor modulator dosage formulations	Mar, 2033 (9 years from now)
US11311516	ALLERGAN HOLDINGS	Opioid receptor modulator dosage formulations	Mar, 2033 (9 years from now)
US10188632	ALLERGAN HOLDINGS	Opioid receptor modulator dosage formulations	Mar, 2033 (9 years from now)
US11484527	ALLERGAN HOLDINGS	Opioid receptor modulator dosage formulations	Mar, 2033 (9 years from now)

Do you want to check out VIBERZI patents from before 2022?

Drugs and Companies using ELUXADOLINE ingredient

Market Authorisation Date: 27 May, 2015

Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline).; Treatment of pain associated with irritable bowel syndrome with diarrhea (ibs-d) with viberzi (eluxadoline); Re...

Dosage: TABLET;ORAL